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ABSTRACT
Recognising and managing wounds at risk of infection is vital in wound management. ALLEVYN Ag dressings have
been designed to manage exudate in chronic wounds that are at risk of infection; are displaying signs of local
infection; or where a suspected increase in bacterial colonisation is delaying healing. They combine an absorbent
silversulfadiazine containing hydrocellular foamlayer,withaperforatedwoundcontactlayerandhighlybreathable
top ﬁlm. The results presented are from a multi-centre clinical evaluation of 126 patients conducted to assess the
performance of ALLEVYN Ag (Adhesive, Non Adhesive and Sacrum dressings) in a range of indications. Clinicians
rated the dressings as acceptable for use in various wound types in 88% of patients. The majority of clinical signs
of infection reduced between the initial and the ﬁnal assessment. The condition of wound tissue and surrounding
skin was observed to improve, and there was signiﬁcant evidence of a reduction in the level of exudate from initial
toﬁnal assessment(p < 0.001). Clinicians rated ALLEVYN Ag as satisfying or exceeding expectations in over 90%
of patients. The evaluation showed the dressings to offer real beneﬁts to patients and clinicians across multiple
indications when used in conjunction with local protocols.
Key words: Bacterial barrier • Exudate management • Infection
INTRODUCTION
Infection in chronic wounds constitutes a
Key Points
• infection in chronic wounds
constitutes a major barrier
to healing and can have an
adverseimpactonthepatient’s
quality of life as well as on the
healing rate of the wound
• prolonged treatment of a
wound because of infection
is undesirable from the health
care provider’s as well as the
patient’s perspective and the
timely use of an effective bac-
terialbarrierdressingregimeto
manage suspected infection is
a key aspect of wound man-
agement
• numerous studies have shown
the beneﬁts of maintaining a
balancedmoistenvironmentat
the wound interface, as this
has been shown to facilitate
closure and to speed up the
healing process
• it is important that modern
wound dressings can maintain
moisture balance by absorbing
excess exudate and preventing
the wound drying out, in
additiontobeingabletoafford
bacterial barrier properties in
wounds which are at risk of
infection, when required
major barrier to healing and can have an
adverse impact on the patient’s quality of
life as well as on the healing rate of the
wound. Infected wounds are likely to be
more painful, hypersensitive and odorous,
resulting in increased discomfort and incon-
venience for the patient (1). In addition,
infected wounds are often associated with
higher exudate levels which can increase the
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number of dressing changes required; the
amountofnursingtimeinvolvedinmanaging
them and the overall cost for the health care
provider. Prolonged treatment of a wound
because of infection is undesirable from the
health care provider’s as well as the patient’s
perspective and the timely use of an effective
bacterial barrier dressing regime to manage
suspected infection is a key aspect of wound
management.
The negative effects of excess exudate on
wound healing are well documented (2); this
can result in delayed healing, maceration of
peri-wound skin and embarrassing leakage
for the patient (3). Numerous studies have,
however, showed the beneﬁts of maintaining
a balanced moist environment at the wound
interface, as this has been shown to facilitate
closure and to speed up the healing pro-
cess (4). It is important that modern wound
dressings can maintain moisture balance by
absorbing excess exudate and preventing the
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wounddryingout,inadditiontobeingableto
afford bacterial barrier properties in wounds
which are at risk of infection, when required.
Chronic wounds are contaminated with
varying levels of bacterial ﬂora, originating
fromthepatientsthemselvesorfromtheenvi-
ronment (5). These micro-organisms respond
to environmental conditions and those in
which they can survive at any one time
depend on the chemical, physical and bio-
logical factors present.
The extent to which these bacteria affect
the healing of the wound is inﬂuenced by the
ability of the patientsimmune system to com-
bat the bacteria (host resistance), the number
of bacteria introduced (higher numbers are
more likely to overcome host resistance) and
the type of bacteria introduced. For example,
somebacteriahavegreaterdisease-producing
ability(virulence)thanothersandmaybeable
to cause disease in relatively low numbers.
Recognising wounds associated with clinical
suspicion of infection or managing wounds
at risk of developing infection is a subject of
intense debate. Although all chronic wounds
contain bacteria, often there is no detrimental
effect. In contaminated wounds, the bacteria
do not increase in number or cause clinical
problems. Bacteria in colonised wounds will
multiply, but will not damage the wound
tissues. In an infected wound, the bacteria
multiply, healing is disrupted and wound
tissues are damaged (local infection). Bacte-
ria may produce problems nearby (spreading
infection) or cause systemic illness (systemic
infection). Localised infection is often char-
acterised by the classic signs and symptoms
of inﬂammation, pain, heat, swelling, redness
and loss of function. However, particularly
in chronic wounds, bacteria may cause prob-
lems such as delayed (or stalled) healing,
in the absence of such obvious indicators of
inﬂammation. Some clinicians refer to this
more subtle state of localised infection as
‘critical colonisation’, or ‘covert’ or ‘occult’
infection (1).Colonisedwoundsundoubtedly
require vigilant monitoring and the timely
use of dressings affording bacterial barrier
properties as well as effective exudate man-
agement may be required where the patient
is atrisk ofinfection, displaying early signs of
local infection or there is a clinical suspicion
that increased bacterial bioburden is slowing
progression to healing.
ALLEVYN Ag dressings, one of the most
recent additions to the ALLEVYN hydrocel-
lular dressing range, have been designed by
Smith and Nephew to provide exudate man-
agement and bacterial barrier properties for
chronic wounds that are at risk of infection,
showingearlysignsoflocalinfectionorwhere
increased bacterial bioburden is suspected to
be delaying healing. ALLEVYN Ag dress-
ings are available in adhesive, non adhesive,
sacrum and heel format.
Key Points
• recognisingwoundsassociated
with clinical suspicion of infec-
tion or managing wounds at
risk of developinginfectionis a
subject of intense debate
• bacteria in colonised wounds
will multiply, but will not
damage the wound tissues
• in an infected wound, the
bacteria multiply, healing is
disrupted and wound tissues
are damaged (local infection)
• ALLEVYN Ag dressings, one
of the most recent additions
to the ALLEVYN hydrocellu-
lar dressing range, have been
designedbySmithandNephew
to provide exudate manage-
ment and bacterial barrier
properties for chronic wounds
that are at risk of infection,
showing early signs of local
infection or where increased
bacterial bioburden is sus-
pected to be delaying healing
• silver is known to kill
pathogens in a variety of
waysbydeactivatingmetabolic
pathways and genetic machin-
eryandbyweakeningbacterial
cell walls and in vitro testing
has showed ALLEVYN Ag to
have bacterial barrier charac-
teristicstoavarietyofbacterial
strains
The dressings feature an advanced triple
layered technology which combines an
absorbent silver sulfadiazine containing
hydrocellularfoamlayer,sandwichedbetween
aperforatedwoundcontactlayerandahighly
breathable top ﬁlm. This unique ‘triple action
technology’ is designed to absorb, retain and
transpire the optimal balance of ﬂuid so
ensuring that a moist wound environment is
maintained to facilitate wound closure while
minimising the risk of peri-wound skin mac-
eration or leakage occurring. Excess exudate
is absorbed into the hydrocellular foam core
inarapidyetcontrolledfashionuponapplica-
tionofthedressing.Onceexudateapproaches
the top of the dressing, it evaporates through
the highly breathable ﬁlm layer. This upper
ﬁlm layer had been designed to respond to
the presence of excess exudate within the
dressing by increasing its moisture vapour
transmission rate. This allows water vapour
to be released at an increased rate so ensuring
that the dressing does not become saturated
but remains comfortable and conformable for
the patient to wear. The ﬁlm layer is, in
addition,awaterproofbacterialbarrierwhich
prevents potential extrinsic contamination of
the wound.
The silver compound, silver sulfadiazine,
incorporated within the dressing was intro-
duced into clinical practice in 1968 and has
been safely used for over half a century as
a topical antimicrobial agent in burns and
other wound types as it is well documented
to be effective against a broad spectrum of
common wound pathogens (6–9). Silver is
known to kill pathogens in a variety of ways
by deactivating metabolic pathways and
genetic machinery and by weakening bacte-
rial cell walls and in vitro testing has showed
ALLEVYN Ag to have bacterial barrier
characteristics to a variety of bacterial strains.
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The combination of excellent exudate man-
agement and bacterial barrier properties pro-
tection afforded by ALLEVYN Ag helps to
overcome two major barriers to wound heal-
ingandpromotesanenvironmentsupportive
of granulation and re-epithelialisation while
preventing peri-wound maceration.
Key Points
• the aim of this evaluation
was to generate data on the
performance of ALLEVYN Ag
adhesive, ALLEVYN Ag non
adhesive and ALLEVYN Ag
sacrum dressings in a clinical
setting on multiple indications
• this was a non comparative
clinical evaluation conducted
acrosssixcountrieswithatotal
of 24 participating centres
• a total of 126 patients were
recruited from the adult (≥18
years) populations routinely
seen by the evaluation clin-
icians from across the UK,
Spain, Ireland, France, Ger-
many and USA
• the study objectives were to
determine whether the dress-
ings were acceptable to clin-
icians for their indicated uses
(primary) and to assess dress-
ing performance parameters
The aim of this evaluation was to generate
data on the performance of ALLEVYN Ag
adhesive, ALLEVYN Ag Non Adhesive and
ALLEVYN Ag Sacrum dressings in a clinical
setting on multiple indications.
This was a non comparative clinical
evaluation conducted across six countries
with a total of 24 participating centres.
METHODS
A multi-centre clinical evaluation (using a
Case report form as data capture on the prod-
uct in use for up to six dressing changes) was
performed between October 2007 and March
2008.
A total of 126 patients were recruited
from the adult ( ≥ 18 years) populations
routinely seen by the evaluation clinicians
from across the UK, Spain, Ireland, France,
GermanyandUSA.Ethicsreviewofthestudy
documentation was not sought prior to the
data collection as the evaluation involved
no change to patient treatment. The product
is available within the countries involved.
There were no patient identiﬁers (name, date
of birth, etc) in the study data capture, and
therefore the study did not require review
by a research ethics committee. Institutional
approval was obtained if required.
The patients recruited were suitable to the
product in accordance with the indications
and contra-indications in the standard prod-
uct insert leaﬂet and were treated according
to the insert leaﬂet’s instructions for use and
standard centre practice throughout the eval-
uation. Consent was given by patients prior
to participation using the centre’s own con-
sent forms which also included consent for
any photographs taken. The evaluation was
in the form of a collection of case studies
documented using a standard data collection
form (provided by Smith & Nephew), which
allowed the data gathered to be pooled and
summarised to provide an understanding of
the uses and performance of the products in
a clinical setting on multiple indications.
No additional procedures, other than com-
pletion of the data collection form and pho-
tography of the wound (if appropriate and
with the patients consent), were performed
during the patient’s participation in this
evaluation. Additional restrictions were not
placed on the patient or on their concomitant
medication/therapies as a result of taking
part in the evaluation.
The following inclusion criteria werespeci-
ﬁed: males or females (not pregnant or lactat-
ing) of at least 18 years of age; patients who
were able to understand and were willing to
consent to the evaluation, and patients who
had an exuding wound present.
If the patient met any of the following
criteria, then they were excluded from the
evaluation: patients with a known history
of poor compliance with medical treatment;
patients who have participated in this
evaluation previously and who healed or
were withdrawn. Other exclusion criteria
werepatientswithknownsensitivity tosilver
sulfadiazine or other product components;
patients with clinically infected wounds
requiring systemic antibiotics and patients
with wounds requiring the use of any other
topical antimicrobial agent on the wound.
The study objectives were to determine
whetherthedressingswereacceptabletoclin-
icians for their indicated uses (primary) and
to assess dressing performance parameters.
Thesewereasfollows:durability (weartime),
whether the dressing was easy to apply and
remove;painonapplicationandremoval;rea-
sons for removal of the dressing; trauma to
thewoundandsurrounding skin onremoval;
adherence to the wound/surrounding skin
(adhesive dressings); patient comfort during
wear; conformability; satisfaction with exu-
date management and leakage, and appear-
ance of the skin (discolouration). Secondary
objectives included assessing changes in the
wound over the course of treatment (max-
imum of six dressing changes) against the
following parameters:
• Clinical signs of infection and whether
the wound was clinically infected
• Wound size
• Wound appearance (tissue types)
• Appearance of surrounding skin
• Exudate level
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Secondary objectives also included deter-
mining whether the clinicians were sufﬁ-
ciently satisﬁed with the dressing’s overall
product performance in terms of exudate
management, bacterial barrier properties (US
centres) or antimicrobial properties (Euro-
pean centres), general ease of use, durability,
patient comfort and convenience.
STATISTICAL METHODS
Wilcoxon’s SignedRankstestwasusedtotest
for a difference in the wound area from initial
to ﬁnal assessment. Cochran–Mantel–Haen-
szel test stratiﬁed by patient was used to
test for a difference in the level of exu-
date between baseline and ﬁnal assessment.
McNemar’s test was used to test for a differ-
ence in the percentage of patients presenting
withanyclinical signs ofinfectionatthebase-
line and ﬁnal assessment. All statistical tests
were two-sided and conducted at the 5% sig-
niﬁcance level.
RESULTS
Patient characteristics
A total of 126 patients were evaluated from
24 centres (16 USA, 8 EU) during the period
September2007–March2008.Themeanageof
patients was 67.8 years (range of 19–99 years)
with a gender distribution of 59 (46.8%)
males and 67 (53.2%) females. Patients were
treated in a variety of settings including
wound clinics (58;46%),hospitals (26;20.6%),
patient’s homes (17; 13.5%), nursing homes
(16; 12.7%) and in a combination of hospital
and patient homes (1; 0.8%) and hospital
and nursing homes (1; 0.8%). The remaining
seven (5.6%) were treated in other treatment
settings, including medical practices for
vascular diseases, long stay centres or nurse
practitioner’s ofﬁces. The median duration
in the study for all patients was 21 days.
At baseline, the median reference wound
duration was 8.7 weeks (range 0.1 weeks to
14 years). Level of pain from the reference
wound was recorded on a visual analogue
scale (VAS) with 0 and 10 representing
no pain and worst pain, respectively. The
majority of patients (84; 68.3%) had no
pain from the reference wound with a
mean pain score of 0.9 (range 0–9.0). The
majority of patients had the reference wound
located on the lower leg (61; 48.4%), foot
(21; 16.7%) or ankle (14; 11.1%), with the
Table 1 Patient wound types
Wound type n %
Venous leg ulcer 37 29.4
Surgical/graft 24 19.0
Pressure ulcer 20 15.9
Mixed/arterial leg ulcer 12 9.5
Traumatic 11 8.7
Diabetic foot ulcer 8 6.3
Burn 7 5.6
Other/unknown 7 5.6
remainderdistributedbetweenanteriortrunk
(11;8.7%),sacrum(7;5.6%),buttocks(4;3.2%),
head/neck (2; 1.6%), arm (2; 1.6%), hand (2;
1.6%) and upper leg (2; 1.6%).
Dressing applications and wound
types
ThepatientwoundtypesreceivingALLEVYN
Ag dressings are summarised in Table 1.
Primary objective
Clinicians assessed the overall acceptability
for 111 patients. The dressings were rated as
acceptable for the majority of patients (98;
88.3%) and wound types.
Secondary objectives
Overall level of satisfaction with the
evaluation dressing. For the majority
of patients, clinicians judged the evalua-
tion dressings as satisfactory or exceeding
expectations with regards to exudate man-
agement,bacterial barrier properties (US cen-
tres), antimicrobial properties (EU centres),
ease of use, durability, patient comfort and
convenience (Figure 1).
Clinical signs of infection
There was signiﬁcant evidence of a reduction
in the percentage of patients presenting with
any clinical signs of infection between the
initial and the ﬁnal assessment (p < 0.001);
corresponding to 79 (68.1%) patients present-
ingwithclinical signsofinfectionattheinitial
assessment reducing to 36 (31.0%) at the ﬁnal
assessment (116 patients assessed at both the
initialandtheﬁnalassessment).Furthermore,
a totalof onlyten(8.5%)patientswerejudged
tohaveaclinically infectedwoundattheﬁnal
assessment (118 patients assessed at both the
initial and the ﬁnal assessment). A reduction
in the majority of clinical signs of infection
between the initial and the ﬁnal assessment
was also observed (Figure 2).
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Figure 1. Overall satisfaction with the dressings.
Figure 2. Percentages of patients exhibiting clinical signs of infection.
Wound size
There was signiﬁcant evidence of a reduction
in the wound area from the initial to
ﬁnal assessment (median reduction = 61%,
p < 0.001). At the initial assessment, the
median wound area was 6.2 cm2,r e d u c i n g
to 1.3 cm2 at the ﬁnal assessment. At the end
of the evaluation, 34 (27%) patients achieved
complete wound closure.
Level of exudate
There was signiﬁcant evidence of a reduction
in the level of exudate from initial to ﬁnal
assessment (p < 0.001) (Figure 3).
Appearance of the reference wound
Overall, the percentage of devitalised tissue
(of the 89 patients who presented with
devitalised tissue) was observed to have
reduced between the initial and the ﬁnal
assessment. Furthermore, over all patients,
there was an increase in healthy tissue at the
ﬁnal assessment (Table 2).
Condition of the surrounding skin
The percentage of patients with healthy
skin was observed to have increased from
the initial to ﬁnal assessment, while the
percentage of patients with unhealthy skin
conditions wasobservedtohave decreasedat
the ﬁnal assessment (Table 3). Figures 4 and
5 show the improvement in one patient.
Product performance parameters
Table 4 shows a summary of the product
performance across dressings.
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Figure 3. Wound exudate levels at the initial assessment and ﬁnal assessment.
Safety
Of the 659 ALLEVYN Ag dressing applica-
tions applied to 126 patients, there were only
ﬁve product complaints over the duration of
theevaluation(0.8%ofdressingapplications).
These were as follows: redness/irritation
(one instance), erythema/excoriation (one
instance), dermatitits (one instance), aller-
gic reaction (one instance) and wound edge
discolouration (one instance). These kinds of
complaints are not unusual given the type of
dressing and wounds being evaluated. This
equates to a low level of product complaints
intermsofexposureandsuggestsnoconcerns
with the safety of the evaluation products.
DISCUSSION
For the majority of patients (88%), ALLEVYN
Ag was rated as acceptable across the
indications treated.Overall, the average wear
time of the dressings was 3.8 days (mean
patient wear time), which may be attributed
to the dressing being changed for routine
reasons in the majority of cases.
The condition of the patients surrounding
skin was observed to improve over the
duration of treatment, with the percentage of
patients with healthy skin increasing and all
otherunhealthyskin conditions decreasingat
the ﬁnal assessment compared to the initial
assessment.
The percentage of patients presenting with
clinical signs of infection present in the
wound and the level of exudate from ini-
tial to ﬁnal assessment were shown to
decrease, both of which are a desirable out-
come in terms of the patient and health
care provider, and shows the value of
these dressings to manage exuding chronic
wounds with the potential for infection
when used in conjunction with local proto-
Key Points
• for the majority of patients
(88%), ALLEVYN Ag was rated
as acceptable across the indi-
cations treated
• the condition of the patients
surroundingskinwas observed
to improve over the dura-
tion of treatment, with the
percentage of patients with
healthy skin increasing and all
otherunhealthyskinconditions
decreasing at the ﬁnal assess-
ment compared to the initial
assessment
cols.
CONCLUSIONS
Product performance
• For the primary objective of the study,
the clinicians rated the dressing as
acceptable in 88% of the patients
included in the evaluation.
• For the secondary objectives, the major-
ity of clinicians judged the dressings to
be satisfactoryorexceeding expectations
with regard to exudate management,
bacterial barrier properties, ease of use,
durability (wear time), patient comfort
and convenience.
Clinical performance
Key Points
• for the primary objective of the
study, the clinicians rated the
dressing as acceptable in 88%
of the patients included in the
evaluation
• for the secondary objectives,
the majority of clinicians
judged the dressings to be sat-
isfactory or exceedingexpecta-
tions with regard to exudate
management, bacterial barrier
properties,easeofuse,durabil-
ity(weartime),patientcomfort
and convenience • There was signiﬁcant evidence of a
reduction in the percentage of patients
presentingwithclinicalsignsofinfection
at the initial and ﬁnal assessment.
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Figure 4. A 65-year-old female with a venous leg ulcer that had been present for 8 weeks. At initial assessment, the wound was
heavily exuding, covered with sloughy tissue, surrounded by erythema and malodorous.
Figure 5. At ﬁnal assessment after ALLEVYN Ag non adhesive was used in conjunction with compression and by the ﬁnal dressing
change, the ulcer was progressing towards closure with 90% of the wound epithelialised.
Wound characteristics
• There was signiﬁcant evidence of a
reduction in the wound area from initial
to ﬁnal assessment.
Key Points
• ALLEVYN Ag is a bacterial
barrier dressing that offers the
following:
• optimal exudate man-
agement leading to
reduced maceration
• active and sustained
reduction in micro-
bial colonisation within
the dressing in chronic
wounds allowing the
host to regain control
and progress the wound
to healing
• a convenient choice
for the management of
critically colonised or
infected chronic wounds
when used in combina-
tion with local clinical
protocols
• Twenty-seven percent of patients had
completeclosure oftheirwoundsduring
a median study period of 21 days.
• There was signiﬁcant evidence of a
reduction in the level of exudate from
initial to ﬁnal assessment.
• The extent of devitalised tissue in the
wound was observed to reduce overall
with a higher percentage of healthy
tissue in the wounds over the course
of up to six dressing changes.
• The condition of the surrounding skin
wasobservedtoimproveoverthecourse
of up to six dressing changes.
ALLEVYNAgisabacterialbarrierdressing
that offers the following:
• Optimalexudatemanagementleadingto
reduced maceration.
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Table 2 Percentage of tissue types in wound bed
Initial assessment Final assessment
Mean % Median % Mean % Median %
Pink (epithelial) tissue 9.5 0 44.8 30
Beefy red granulation 26.4 10 31.3 12.5
Dull red tissue 13.2 0 7.6 0
Friable granulation tissue 12.6 0 6.7 0
Yellow sloughy tissue 29.6 20 15.3 0
Black necrotic tissue 2.2 0 1.8 0
Devitalised tissue (patients with devitalised tissue at baseline) 44.1 50.0 21.4 10.0
Devitalised tissue (patients without devitalised tissue at baseline) 0 0 5.5 0
Table 3 Condition of the surrounding skin
Initial assessment Final assessment
n % n %
Healthy skin 43 34.1 69 58.5
Inﬂamed 40 31.7 19 16.1
Macerated 27 21.4 9 7.6
Dry and ﬂaky 20 15.9 7 5.9
Other 20 15.9 11 9.3
Table 4 Product performance parameters
Product performance Percentage of
parameter dressing changes
Dressing easy to apply 98.0%
Dressing easy to remove 99.2%
Comfortable to wear 97.7%
Good/acceptable dressing
conformability
On application 99.8%
During wear 99.6%
No discolouration to
surrounding skin
67.8%
Slight discolouration to
surrounding skin
24.8%
No pain on dressing
application
80.4%
No pain on dressing removal 78.6%
Adhesive dressings fully
adhered
On application 91.6%
Prior to removal 76.8%
Satisﬁed with exudate and
leakage handling of
dressing
95.2%
Dressings changed for
routine reasons
90.8%
Mean (min, max)
Wear time (overall patients) 3.8 days (range 1–7.2)
• Activeandsustainedreductioninmicro-
bial colonisation within the dressing in
chronic wounds allowing the host to
regain control and progress the wound
to healing.
• Aconvenientchoiceforthemanagement
of critically colonised or infected chronic
wounds when used in combination with
local clinical protocols.
 ALLEVYN is a trademark of Smith &
Nephew
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